Vesigen to Present New Preclinical Data on Ophthalmology Applications of Engineered ARMMs at ARVO

Vesigen Therapeutics announced that the company will be presenting two posters sharing new preclinical data from its engineered ARMMs platform at the upcoming Association for Research in Vision and Ophthalmology (ARVO) annual meeting in Seattle, from May 5-9.

Vesigen’s technology comprises engineered forms of a class of naturally existing vesicles designed to enable efficient functional delivery of complex intracellular payloads, while overcoming challenges observed with other modalities such as tissue specificity, toxicity, and re-dosability.

Vesigen will present preclinical data demonstrating successful biodistribution of its engineered ARMMs to non-human primate (NHP) photoreceptors and retinal pigment epithelium. The company will also share new preclinical NHP data demonstrating functional delivery of genome editors to the retina and supporting therapeutic use of ARMMs in ocular diseases.

Details of the poster presentations are listed below. For more information about the ARVO Annual Meeting, including registration details, visit https://www.arvo.org/annual-meeting/.

ARMMs as Non-viral Vehicles for the Delivery of Genome Editors to Treat Stargardt Disease

• Poster Number: A0081
• Date: May 6 at 3:00pm EST
• Session: 245
• Location: Exhibit Hall

Biodistribution of ARMMs as Non-Viral Vehicles for Therapeutic Payloads by Sub-Retinal Administration in Minipigs and NHP

• Poster Number: B0291
• Date: May 8 at 2:15pm EST
• Session: 449
• Location: Exhibit Hall